A Phase 1/2 interventional study of Blinatumomab in Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia, sponsored by Amgen. Completed at 16 sites in Japan. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2022-12-12.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 32nd largest by enrollment, is one of 2 that started in 2015, is one of 8 in phase 1/2, and was the 9th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, France, Israel and 3 more countries
Ages 1–30
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1 mo–18 yrs
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 41 · Phase 3 14 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 67 across the 61 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 61 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen: 1 open now, 3 under way, 2 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2015, is one of 3 in phase 1/2, and was the 12th registered.
Amgen’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 2005.
11 of the studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT04722848Phase 3Gruppo Italiano Malattie EMatologiche dell'AdultoSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | 2027-09 |
| NCT06387121Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | 2026-12-01 |
| NCT03114865Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsA Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | 2026-12-30 |
| NCT05519579Northside Hospital, Inc.Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Among Amgen’s 20 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, combined 2-part multicenter study to evaluate the efficacy, safety, and tolerability of blinatumomab in adult and pediatric Japanese patients with relapsed/refractory B-precursor ALL.
The Phase 1b part will investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of blinatumomab to determine the maximum tolerated dose (MTD) in both adult and pediatric Japanese patients with relapsed/refractory B-precursor ALL. The Phase 2 part will assess the safety and efficacy of the recommended dose level of blinatumomab identified in the Phase 1b portion of the study in the adult study population.
In June 2017 protocol amendment 4 extended the study to include an expansion cohort of approximately 65 participants to investigate the safety of blinatumomab in participants who did not participate in Phase 1b or Phase 2 of the study. Adult and pediatric patients in the expansion cohort may receive up to 5 cycles of investigational blinatomumab and may receive commercial blinatomumab after a minimum of 2 cycles of the investigational drug.
Adult Subjects Key Inclusion Criteria:
Subjects with Philadelphia-negative B-precursor ALL, with any of the following:
Pediatric Subjects Key Inclusion Criteria:
Relapsed/refractory disease, defined as one of the following:
Refractory to other treatments:
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
Drug: Blinatumomab
Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
Drug: Blinatumomab
Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
Drug: Blinatumomab
Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
Drug: Blinatumomab
Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
Drug: Blinatumomab
Continuous intravenous infusion over four weeks per treatment cycle
Also known as: Blincyto®
Phase 1b: Number of Participants With Dose-limiting Toxicities
Dose-limiting toxicities (DLTs) were defined as any Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade ≥ 3 adverse event related to blinatumomab, excluding specific CTCAE grade ≥ 3 adverse events considered consistent with the current known safety profile of blinatumomab, CTCAE grade ≥ 3 fever or infection, and laboratory parameters of CTCAE grade ≥ 3 not considered clinically relevant and/or responding to routine medical management.
Time frame: Days 1 to 14
Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.
Time frame: Within the first 2 cycles of treatment, 12 weeks
Expansion Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs
TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.
Time frame: From the start of the first infusion to 30 days after the end of the last infusion; median (min, max) treatment duration was 55.6 (25, 140) and 28.0 (8, 56) days in the adult and pediatric expansion cohorts, respectively.
Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl
Time frame: Within the first 2 cycles of treatment, 12 weeks
Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment
M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.
Time frame: The first 2 cycles of treatment, 12 weeks
Phase 1b and Phase 2: Duration of Response
Duration of response was calculated from the date of bone marrow aspiration when response (CR/CRh\*) was detected for the first time during the first 2 cycles of treatment until the earlier of the following events: * the date of bone marrow aspiration at which hematological relapse or progressive disease (PD) was first detected, * the date of diagnosis on which the hematological or extra medullary relapse was documented, * the date of death if patient died due to PD * the date of end of induction phase if primary reason for treatment termination was hematological or extramedullary relapse. For a responder who did not report an event and was alive during the study, the end date of duration (censoring) was based on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis. Participants with response who did not report an event and who died due to reasons other than PD, were censored on the date of death, with death treated as a competing risk.
Time frame: Median (minimum [min], maximum [max]) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.
Phase 1b and Phase 2: Relapse-free Survival
Relapse-free survival (RFS) was defined for participants who achieved a response (CR/CRh\*) during the first 2 cycles of treatment. RFS was calculated from the date of bone marrow aspiration when response was detected for the first time to the date of bone marrow aspiration at which hematological relapse was first detected or the date of diagnosis on which the hematological or extra medullary relapse was documented or the date of death due to any cause, whichever was earlier. Participants who did not experience hematological relapse and did not die were censored on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis.
Time frame: Median (min, max) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.
Phase 1b and Phase 2: Overall Survival
Overall survival (OS) was calculated from the start date of blinatumomab infusion in the first treatment cycle. All deaths were counted as events on the date of death. Participants still alive were censored on the last documented visit date or the date of the last phone contact when the participant was last known to have been alive. For participants who withdrew their informed consent, only information until the date of withdrawal was used in the analysis.
Time frame: Median (min, max) follow-up time was 6.3 (2.4, 13.6) months for Phase 1b and 26.7 (3.0, 28.5) months for Phase 2.
Phase 2: Best Overall Response Within 2 Cycles of Treatment
Best response was defined as one of the following: CR: ≤ 5% blasts in the bone marrow (BM); No evidence of disease; Full recovery of peripheral blood counts: Platelets \> 100,000/µl, and absolute neutrophil count (ANC) \> 1,000/µl CRh\*: ≤ 5% blasts in BM; No evidence of disease; Partial recovery of peripheral blood counts: Platelets \> 50,000/µl, and ANC \> 500/µl CRi: CR with incomplete count recovery without CRh\* Blast free hypoplastic or aplastic BM: ≤ 5 % blasts in BM; No evidence of disease; Insufficient recovery of peripheral blood counts: platelets ≤ 50,000/µl and/or ANC ≤ 500/µl Partial Remission: BM blasts \> 5 to \< 25% with at least a 50% reduction from baseline Hematological Relapse: \> 5% blasts in BM or blasts in peripheral blood after documented CR/CRh\* during the study PD: An increase from baseline of ≥ 25% of BM blasts or an absolute increase of ≥ 5,000 cells/µL in the number of circulating leukemia cells.
Time frame: Within the first 2 cycles of treatment, 12 weeks
Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission
Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.
Time frame: Median (min, max) follow-up time was 26.7 (3.0, 28.5) months.
Phase 2: 100-Day Mortality After Allogeneic HSCT
The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in any CR following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. Participants still alive alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.
Time frame: 100 days, from the date of allogeneic HSCT; median (min, max) follow-up time was 26.7 (3.0, 28.5)
Phase 1b and Phase 2: Number of Participants With TEAEs
TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.
Time frame: From the start of the first infusion to 30 days after the end of the last infusion; median (min, max) treatment duration was 108 (56, 140), 56.0 (5, 84), and 56.0 (11, 115) days in adult phase 1b, adult phase 2 and pediatric phase 1b cohort respectively.
Phase 1b and Phase 2: Serum Blinatumomab Concentration at Steady State
The steady-state concentration (Css) of serum blinatumomab was summarized as the average of the observed concentrations collected after 5 half-lives or after 24 hours from the start of continuous IV infusion. Cycle 1, day 2 values represent steady-state concentration after CIV with the initial dose of blinatumomab (9 µg/day for adults and 5 µg/m²/day for pediatric patients). All other time points were measured after the dose step to 28 µg/day (adults) / 15 µg/m²/day (pediatric participants).
Time frame: After 24 hours from the start of infusion: Cycle 1 (before dose step) day 2; Cycle 1 (after dose step) days 15 and 29; Cycle 2 onwards day 8 (pediatric and adult), days 15 and 29 (adult).
Phase 1b and Phase 2: Systemic Clearance of Blinatumomab
Systemic clearance (CL) was calculated as CL = R0/Css, where R0 is the infusion rate (µg/hour or µg/m²/hour).
Time frame: After 24 hours from the start of infusion: Cycle 1 (before dose step) day 2; Cycle 1 (after dose step) days 15 and 29; Cycle 2 onwards day 8 (pediatric and adult), days 15 and 29 (adult).
Phase 1b and Phase 2: Terminal Half-life of Blinatumomab
Time frame: Cycle 1 day 1 predose, 2, 6 (adults), 10, 24 hours; day 8 (prior to dose step) 0 hour (adults); day 15 any time during infusion; day 29 prior to end of infusion, 1 (adults), 2, 4 (adults), 6 hours after end of infusion
Phase 1b and Phase 2: Volume of Distribution of Blinatumomab
Time frame: Cycle 1 day 1 predose, 2, 6 (adults), 10, 24 hours; day 8 (prior to dose step) 0 hour (adults); day 15 any time during infusion; day 29 prior to end of infusion, 1 (adults), 2, 4 (adults), 6 hours after end of infusion
Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies
Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.
Time frame: Day 1 before first dose; cycles 1 and 2 day 29, 6 hours after end of infusion; 30 days after last dose.
Phase 1b and Phase 2: Interleukin-2 Concentration
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Phase 1b and Phase 2: Interleukin-6 Concentration
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Phase 1b and Phase 2: Interleukin-10 Concentration
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Phase 1b and Phase 2: Tumor Necrosis Factor-Alpha (TNFα) Concentration
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Phase 1b and Phase 2: Interferon Gamma (IFN-γ) Concentration
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
Time frame: Adults: cycle 1, day 1: 2, 6, 10, 24 hrs after infusion start; day 8: 2, 6, 10 hrs after dose step. Cycles 2-5, day 1: 6 hrs after infusion start. Pediatric: cycle 1, day 1: 6, 10, 24 hrs after infusion start; Cycles 2-5, day 1: 6 hrs after infusion start
Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.
Time frame: Within the first 2 cycles of treatment, 12 weeks
Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment
M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.
Time frame: Within the first 2 cycles of treatment, 12 weeks
Study was conducted at 16 centers in Japan. Cohort enrollment periods were: adult phase 1b, from 04 Jun 2015 to 13 Jan 2016; pediatric phase 1b, from 17 Feb 2016 to 20 Jun 2016; adult phase 2, from 11 Apr 2016 to 12 Jun 2017; adult expansion cohort, from 04 Dec 2017 to 13 Nov 2018; pediatric expansion cohort, from 05 Nov 2017 to 05 Sep 2018.
| Milestone | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|---|---|---|
| Started | 5 | 9 | 21 | 14 | 17 |
| Completed | 0 | 1 | 5 | 14 | 15 |
| Not completed | 5 | 8 | 16 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 5 | 7 | 15 | 0 | 2 |
Dose-limiting toxicities (DLTs) were defined as any Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade ≥ 3 adverse event related to blinatumomab, excluding specific CTCAE grade ≥ 3 adverse events considered consistent with the current known safety profile of blinatumomab, CTCAE grade ≥ 3 fever or infection, and laboratory parameters of CTCAE grade ≥ 3 not considered clinically relevant and/or responding to routine medical management.
| Participants | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| Phase 1b: Number of Participants With Dose-limiting Toxicities | 0 | 0 |
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.
| percentage of participants | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|
| Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment | 38.1 (18.1 to 61.6) |
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl
| percentage of participants | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|
| Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment | 80.0 (28.4 to 99.5) |
M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.
| percentage of participants | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|
| Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment | 55.6 (21.2 to 86.3) |
Duration of response was calculated from the date of bone marrow aspiration when response (CR/CRh\*) was detected for the first time during the first 2 cycles of treatment until the earlier of the following events: * the date of bone marrow aspiration at which hematological relapse or progressive disease (PD) was first detected, * the date of diagnosis on which the hematological or extra medullary relapse was documented, * the date of death if patient died due to PD * the date of end of induction phase if primary reason for treatment termination was hematological or extramedullary relapse. For a responder who did not report an event and was alive during the study, the end date of duration (censoring) was based on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis. Participants with response who did not report an event and who died due to reasons other than PD, were censored on the date of death, with death treated as a competing risk.
| months | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|---|---|
| Phase 1b and Phase 2: Duration of Response | 13.0 (4.2 to 19.7) | 2.3 (1.1 to 6.8) | 13.1 (3.5 to 20.7) |
Relapse-free survival (RFS) was defined for participants who achieved a response (CR/CRh\*) during the first 2 cycles of treatment. RFS was calculated from the date of bone marrow aspiration when response was detected for the first time to the date of bone marrow aspiration at which hematological relapse was first detected or the date of diagnosis on which the hematological or extra medullary relapse was documented or the date of death due to any cause, whichever was earlier. Participants who did not experience hematological relapse and did not die were censored on the date of the last available bone marrow aspiration prior to the data cutoff date for the analysis.
| months | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|---|---|
| Phase 1b and Phase 2: Relapse-free Survival | 11.4 (4.2 to 19.7) | 2.3 (1.1 to 6.8) | 13.1 (3.5 to 20.7) |
Overall survival (OS) was calculated from the start date of blinatumomab infusion in the first treatment cycle. All deaths were counted as events on the date of death. Participants still alive were censored on the last documented visit date or the date of the last phone contact when the participant was last known to have been alive. For participants who withdrew their informed consent, only information until the date of withdrawal was used in the analysis.
| months | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|---|---|
| Phase 1b and Phase 2: Overall Survival | 11.0 (9.3 to 20.7) | 10.6 (0.9 to NA) | 14.8 (2.7 to 21.6) |
Best response was defined as one of the following: CR: ≤ 5% blasts in the bone marrow (BM); No evidence of disease; Full recovery of peripheral blood counts: Platelets \> 100,000/µl, and absolute neutrophil count (ANC) \> 1,000/µl CRh\*: ≤ 5% blasts in BM; No evidence of disease; Partial recovery of peripheral blood counts: Platelets \> 50,000/µl, and ANC \> 500/µl CRi: CR with incomplete count recovery without CRh\* Blast free hypoplastic or aplastic BM: ≤ 5 % blasts in BM; No evidence of disease; Insufficient recovery of peripheral blood counts: platelets ≤ 50,000/µl and/or ANC ≤ 500/µl Partial Remission: BM blasts \> 5 to \< 25% with at least a 50% reduction from baseline Hematological Relapse: \> 5% blasts in BM or blasts in peripheral blood after documented CR/CRh\* during the study PD: An increase from baseline of ≥ 25% of BM blasts or an absolute increase of ≥ 5,000 cells/µL in the number of circulating leukemia cells.
| Participants | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|
| CR | 5 |
| CRh* | 3 |
| CRi | 0 |
| Blast-free hypoplastic or aplastic bone marrow | 6 |
| Partial remission | 0 |
| Hematological relapse | 0 |
| PD | 2 |
| No response (none of the above) | 5 |
Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.
| percentage of participants | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|
| Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission | 81.0 |
The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in any CR following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. Participants still alive alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.
| percentage of participants | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|
| Phase 2: 100-Day Mortality After Allogeneic HSCT | 11.8 |
TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.
| Participants | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|---|---|
| All TEAEs | 5 | 9 | 21 |
| TEAEs ≥ Grade 3 | 4 | 9 | 21 |
| TEAEs ≥ Grade 4 | 2 | 7 | 14 |
| Serious TEAEs (STEAEs) | 0 | 1 | 7 |
| TEAEs Leading to Blinatumomab Interruption | 1 | 6 | 3 |
| STEAEs Leading to Blinatumomab Interruption | 0 | 0 | 0 |
| TEAEs Leading to Blinatumomab Discontinuation | 0 | 1 | 1 |
| STEAEs Leading to Blinatumomab Discontinuation | 0 | 0 | 1 |
| Fatal TEAEs | 0 | 1 | 1 |
| All Treatment-Related (TR) TEAEs | 5 | 8 | 21 |
| TR TEAEs ≥ Grade 3 | 2 | 8 | 18 |
| TR TEAEs ≥ Grade 4 | 1 | 5 | 11 |
| TR STEAEs | 0 | 0 | 4 |
| TR TEAEs Leading to Blinatumomab Interruption | 1 | 6 | 1 |
| TR STEAEs Leading to Blinatumomab Interruption | 0 | 0 | 0 |
| TR TEAEs Leading to Blinatumomab Discontinuation | 0 | 1 | 1 |
| TR STEAEs Leading to Blinatumomab Discontinuation | 0 | 0 | 1 |
| TR Fatal TEAEs | 0 | 0 | 0 |
The steady-state concentration (Css) of serum blinatumomab was summarized as the average of the observed concentrations collected after 5 half-lives or after 24 hours from the start of continuous IV infusion. Cycle 1, day 2 values represent steady-state concentration after CIV with the initial dose of blinatumomab (9 µg/day for adults and 5 µg/m²/day for pediatric patients). All other time points were measured after the dose step to 28 µg/day (adults) / 15 µg/m²/day (pediatric participants).
| pg/mL | Blinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric) | Blinatumomab 9/28 μg/Day (Phase 1b Only Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric) |
|---|---|---|---|---|
| Cycle 1 before dose step | 191 ± 90.8 | 113 ± 65.0 | 135 ± 41.7 | 107 ± 42.7 |
| Cycle 1 after dose step | 948 ± 488 | 361 ± 137 | 907 ± 403 | 361 ± 137 |
| Cycle 2 | 1150 ± 575 | 427 ± 66.0 | 1040 ± 493 | 427 ± 66.0 |
| Cycle 3+ | 1420 ± 685 | 780 ± NA | 1280 ± 396 | — |
Systemic clearance (CL) was calculated as CL = R0/Css, where R0 is the infusion rate (µg/hour or µg/m²/hour).
| liters/hour | Blinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric) | Blinatumomab 9/28 μg/Day (Phase 1b Only Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric) |
|---|---|---|---|---|
| Phase 1b and Phase 2: Systemic Clearance of Blinatumomab | 1.59 ± 0.812 | 1.88 ± 0.789 | 1.59 ± 0.998 | 1.83 ± 0.801 |
| hours | Blinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric) | Blinatumomab 9/28 μg/Day (Phase 1b Only Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric) |
|---|---|---|---|---|
| Phase 1b and Phase 2: Terminal Half-life of Blinatumomab | 2.38 ± 1.36 | 1.92 ± 1.12 | 2.60 ± 2.03 | 2.62 ± 1.67 |
| liters | Blinatumomab 9/28 μg/Day (Phase 1b and Phase 2 Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b and Phase 2 Pediatric) | Blinatumomab 9/28 μg/Day (Phase 1b Only Adults) | Blinatumomab 5/15 µg/m²/Day (Phase 1b Only Pediatric) |
|---|---|---|---|---|
| Phase 1b and Phase 2: Volume of Distribution of Blinatumomab | 6.02 ± 6.09 | 5.05 ± 3.35 | 8.22 ± 11.7 | 6.38 ± 3.95 |
Antibodies to blinatumomab were detected using an electrochemiluminescence (ECL)-based assay.
| Participants | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|---|---|
| Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies | 0 | 0 | 0 |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
| pg/mL | Phase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| Cycle 1, day 1, 2 hours after start of infusion | 16.1 ± 17.1 | — |
| Cycle 1, day 1, 6 hours after start of infusion | 30.2 ± 72.8 | 10.0 ± 0.0 |
| Cycle 1, day 1, 10 hours after start of infusion | 32.6 ± 85.0 | 10.0 ± 0.0 |
| Cycle 1, day 1, 24 hours after start of infusion | 17.2 ± 36.7 | 29.8 ± 55.9 |
| Cycle 1, day 8, 2 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 1, day 8, 6 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 1, day 8, 10 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 2, day 1, 6 hours after start of infusion | 12.6 ± 11.7 | 10.0 ± 0.0 |
| Cycle 3, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± 0.0 |
| Cycle 4, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± NA |
| Cycle 5, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± NA |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
| pg/mL | Phase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| Cycle 1, day 1, 2 hours after start of infusion | 29.1 ± 40.1 | — |
| Cycle 1, day 1, 6 hours after start of infusion | 173 ± 198.1 | 275 ± 371 |
| Cycle 1, day 1, 10 hours after start of infusion | 186 ± 301.5 | 317 ± 358 |
| Cycle 1, day 1, 24 hours after start of infusion | 246 ± 907.6 | 3714 ± 10740 |
| Cycle 1, day 8, 2 hours after start of infusion | 14.2 ± 14.5 | — |
| Cycle 1, day 8, 6 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 1, day 8, 10 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 2, day 1, 6 hours after start of infusion | 20.3 ± 35.6 | 17.5 ± 19.8 |
| Cycle 3, day 1, 6 hours after start of infusion | 16.6 ± 18.6 | 36.3 ± 37.1 |
| Cycle 4, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 62.5 ± NA |
| Cycle 5, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 62.5 ± NA |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
| pg/mL | Phase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| Cycle 1, day 1, 2 hours after start of infusion | 101 ± 81.1 | — |
| Cycle 1, day 1, 6 hours after start of infusion | 597 ± 637 | 153 ± 94.7 |
| Cycle 1, day 1, 10 hours after start of infusion | 423 ± 373 | 230 ± 178 |
| Cycle 1, day 1, 24 hours after start of infusion | 400 ± 699 | 641 ± 1168 |
| Cycle 1, day 8, 2 hours after start of infusion | 28.9 ± 25.7 | — |
| Cycle 1, day 8, 6 hours after start of infusion | 33.1 ± 26.6 | — |
| Cycle 1, day 8, 10 hours after start of infusion | 33.1 ± 26.6 | — |
| Cycle 2, day 1, 6 hours after start of infusion | 220 ± 357 | 142 ± 173 |
| Cycle 3, day 1, 6 hours after start of infusion | 121 ± 146 | 62.5 ± 0.0 |
| Cycle 4, day 1, 6 hours after start of infusion | 88.2 ± 93.7 | 62.5 ± NA |
| Cycle 5, day 1, 6 hours after start of infusion | 36.3 ± 37.1 | 62.5 ± NA |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
| pg/mL | Phase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| Cycle 1, day 1, 2 hours after start of infusion | 37.3 ± 61.8 | — |
| Cycle 1, day 1, 6 hours after start of infusion | 24.1 ± 23.7 | 15.8 ± 17.5 |
| Cycle 1, day 1, 10 hours after start of infusion | 20.1 ± 21.1 | 15.8 ± 17.5 |
| Cycle 1, day 1, 24 hours after start of infusion | 10.0 ± 0.0 | 15.8 ± 17.5 |
| Cycle 1, day 8, 2 hours after start of infusion | 16.6 ± 32.8 | — |
| Cycle 1, day 8, 6 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 1, day 8, 10 hours after start of infusion | 10.0 ± 0.0 | — |
| Cycle 2, day 1, 6 hours after start of infusion | 12.6 ± 11.7 | 17.5 ± 19.8 |
| Cycle 3, day 1, 6 hours after start of infusion | 16.6 ± 18.6 | 10.0 ± 0.0 |
| Cycle 4, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± NA |
| Cycle 5, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± NA |
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) was 125 pg/mL and the limit of detection (LOD) was 20 pg/mL. For calculations of mean cytokine concentrations at every time point across all participants, samples with concentrations below LLOQ were included in the calculation as ½ LLOQ (= 62.5 pg/mL); samples with values below LOD were included as ½ LOD (= 10 pg/mL).
| pg/mL | Phase 1b and Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b and Phase 2: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| Cycle 1, day 1, 2 hours after start of infusion | 26.2 ± 24.7 | — |
| Cycle 1, day 1, 6 hours after start of infusion | 52.3 ± 56.2 | 41.2 ± 42.8 |
| Cycle 1, day 1, 10 hours after start of infusion | 65.8 ± 71.6 | 64.5 ± 107 |
| Cycle 1, day 1, 24 hours after start of infusion | 42.1 ± 51.8 | 129 ± 176 |
| Cycle 1, day 8, 2 hours after start of infusion | 16.3 ± 17.4 | — |
| Cycle 1, day 8, 6 hours after start of infusion | 14.2 ± 14.5 | — |
| Cycle 1, day 8, 10 hours after start of infusion | 14.2 ± 14.5 | — |
| Cycle 2, day 1, 6 hours after start of infusion | 17.9 ± 19.2 | 40.0 ± 28.1 |
| Cycle 3, day 1, 6 hours after start of infusion | 35.8 ± 55.0 | 10.0 ± 0.0 |
| Cycle 4, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± NA |
| Cycle 5, day 1, 6 hours after start of infusion | 10.0 ± 0.0 | 10.0 ± NA |
TEAEs are defined as those that start between the start of the first infusion of blinatumomab and 30 days after the end of the last infusion during the treatment period. The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab.
| participants | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|
| All TEAEs | 14 | 17 |
| TEAEs ≥ Grade 3 | 11 | 15 |
| TEAEs ≥ Grade 4 | 7 | 7 |
| Serious TEAEs (STEAEs) | 2 | 3 |
| TEAEs Leading to Interruption of Blinatumomab | 2 | 2 |
| STEAEs Leading to Interruption of Blinatumomab | 0 | 0 |
| TEAEs Leading to Blinatumomab Discontinuation | 0 | 1 |
| STEAEs Leading to Blinatumomab Discontinuation | 0 | 0 |
| Fatal TEAEs | 0 | 2 |
| All Treatment-Related (TR) TEAEs | 14 | 14 |
| TR TEAEs ≥ Grade 3 | 9 | 9 |
| TR TEAEs ≥ Grade 4 | 5 | 5 |
| TR STEAEs | 0 | 0 |
| TR TEAEs Leading to Blinatumomab Interruption | 2 | 1 |
| TR STEAEs Leading to Blinatumomab Interruption | 0 | 0 |
| TR TEAEs Leading to Blinatumomab Discontinuation | 0 | 1 |
| TR STEAEs Leading to Blinatumomab Discontinuation | 0 | 0 |
| TR Fatal TEAEs | 0 | 0 |
Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: * Complete Remission (CR) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets \> 100,000/µl and absolute neutrophil count (ANC) \> 1,000/µl. * Complete Remission With Partial Hematological Recovery (CRh\*) is defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts: platelets \> 50,000/µl and ANC \> 500/µl.
| percentage of participants | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) |
|---|---|
| Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment | 78.6 (49.2 to 95.3) |
M1 remission for pediatric participants was defined as ≤ 5% blasts (M1 bone marrow) in the bone marrow and no evidence of disease.
| percentage of participants | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|
| Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment | 29.4 (10.3 to 56.0) |
Collected over The median treatment duration for blinatumomab was 108 days for Adult Phase 1b Cohort, 56 days for Pediatric Phase 1b Cohort, 56 days for Adult Phase 2 Cohort, 55.6 days for Adult Expansion Cohort and 28 days for Pediatric Expansion Cohort. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | 5/5 (100%) | 0/5 (0%) | 5/5 (100%) |
| Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | 7/9 (77.8%) | 1/9 (11.1%) | 9/9 (100%) |
| Phase 2: Blinatumomab 9/28 μg/Day (Adults) | 15/21 (71.4%) | 7/21 (33.3%) | 21/21 (100%) |
| Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | 0/14 (0%) | 2/14 (14.3%) | 14/14 (100%) |
| Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) | 2/17 (11.8%) | 3/17 (17.6%) | 16/17 (94.1%) |
| Event | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/5 | 0/9 | 0/21 | 0/14 | 2/17 |
| Shock haemorrhagicVascular disorders | 0/5 | 1/9 | 0/21 | 0/14 | 0/17 |
| Neutrophil count decreasedInvestigations | 0/5 | 0/9 | 2/21 | 0/14 | 0/17 |
| BacteraemiaInfections and infestations | 0/5 | 0/9 | 1/21 | 1/14 | 0/17 |
| StomatitisGastrointestinal disorders | 0/5 | 0/9 | 0/21 | 1/14 | 0/17 |
| Disease progressionGeneral disorders | 0/5 | 0/9 | 0/21 | 0/14 | 1/17 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/5 | 0/9 | 0/21 | 0/14 | 1/17 |
| OverdoseInjury, poisoning and procedural complications | 0/5 | 0/9 | 0/21 | 0/14 | 1/17 |
| ColitisGastrointestinal disorders | 0/5 | 0/9 | 1/21 | 0/14 | 0/17 |
| Cytokine release syndromeImmune system disorders | 0/5 | 0/9 | 1/21 | 0/14 | 0/17 |
| Event | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/5 | 7/9 | 15/21 | 4/14 | 15/17 |
| Cytokine release syndromeImmune system disorders | 4/5 | 5/9 | 8/21 | 5/14 | 6/17 |
| HeadacheNervous system disorders | 3/5 | 4/9 | 6/21 | 3/14 | 4/17 |
| NauseaGastrointestinal disorders | 2/5 | 2/9 | 9/21 | 8/14 | 2/17 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/5 | 5/9 | 10/21 | 7/14 | 4/17 |
| NeutropeniaBlood and lymphatic system disorders | 2/5 | 5/9 | 5/21 | 6/14 | 0/17 |
| VomitingGastrointestinal disorders | 2/5 | 5/9 | 3/21 | 4/14 | 6/17 |
| Alanine aminotransferase increasedInvestigations | 1/5 | 5/9 | 4/21 | 2/14 | 6/17 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/5 | 5/9 | 2/21 | 0/14 | 4/17 |
| AnaemiaBlood and lymphatic system disorders | 1/5 | 4/9 | 7/21 | 4/14 | 6/17 |
| Age, Customized(Participants) | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Total |
|---|---|---|---|---|---|---|
| < 2 years | 0 | 0 | 0 | 0 | 1 | 1 |
| 2 to 6 years | 0 | 0 | 0 | 0 | 5 | 5 |
| 7 to 17 years | 0 | 9 | 0 | 0 | 11 | 20 |
| 18 to 34 years | 1 | 0 | 6 | 5 | 0 | 12 |
| 35 to 54 years | 1 | 0 | 14 | 6 | 0 | 21 |
| 55 to 64 years | 2 | 0 | 1 | 1 | 0 | 4 |
| ≥ 65 years | 1 | 0 | 0 | 2 | 0 | 3 |
| Sex: Female, Male(Participants) | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 5 | 12 | 9 | 8 | 38 |
| Male | 1 | 4 | 9 | 5 | 9 | 28 |
| Race/Ethnicity, Customized(Participants) | Phase 1b: Blinatumomab 9/28 μg/Day (Adults) | Phase 1b: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Phase 2: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 9/28 μg/Day (Adults) | Expansion Cohort: Blinatumomab 5/15 µg/m²/Day (Pediatric) | Total |
|---|---|---|---|---|---|---|
| Japanese | 5 | 9 | 21 | 14 | 17 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jun 2015 to primary completion in Feb 2019, 44 months.
Results were first posted in Jan 2020, 11 months after primary completion.
Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's 44 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Precursor Cell Lymphoblastic Leukemia-Lymphoma →